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Abstract: A new progesterone antagonist, ulipristal has been made available as an emergency 
contraceptive. Ulipristal’s major mechanism of action as an emergency contraceptive has 
been ascribed to its ability to delay ovulation beyond the life span of the sperm. This paper 
analyzes the potential action of ulipristal (1) when unprotected intercourse and administration 
of ulipristal occur outside the fertility window and (2) when unprotected intercourse and 
administration of ulipristal occur at or within 24 hours of ovulation. When unprotected 
intercourse and the use of a single low dose of ulipristal occur outside of the fertility window, 
ulipristal behaves like a placebo. When unprotected intercourse and the use of a single low 
dose of ulipristal occur within the fertility window but before ovulation, ulipristal behaves 
like an emergency contraceptive by delaying ovulation and thereby preventing fertilization. 
When unprotected intercourse and the administration of ulipristal occur at or within 24 hours 
of ovulation, then ulipristal has an abortifacient action. It is proposed that the abortifacient 
mechanism of a low dose of ulipristal taken after fertilization but before implantation is due to 
the ability of ulipristal to block the maternal innate immune system to become immunotolerant 
to the paternal allogenic embryo. Progesterone’s critical immunotolerant actions involving 
early pregnancy factor, progesterone-induced blocking factor, and uterine natural killer cells 
are compromised by ulipristal.
Keywords: innate immune system, early pregnancy factor, progesterone-induced blocking 
factor, uterine natural killer cells, selective progesterone receptor modulator
Introduction
Ulipristal is a progesterone antagonist that is being used as an emergency contra-
ceptive (EC) to delay ovulation beyond the life span of the sperm and thus prevent 
fertilization. This paper describes an additional hypothesis that suggests that ulipristal 
in certain circumstances blocks the immunotolerance effects of progesterone on the 
maternal innate immune system (mIIS), resulting in the immunorejection of an embryo 
attempting to implant.
Progesterone in pregnancy
Progesterone exerts its hormonal effects by binding to specific genomic and 
nongenomic receptors.1,2 Progesterone regulates the inflammatory processes in the 
human endometrium during both menstruation and implantation of the embryo.3,4 
  Inadequate progesterone synthesis results in spontaneous abortions.5 Progesterone has 
  immunomodulating effects on dendritic cells from female mice that result in inhibition 
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Class II expression and decreased T-cell proliferation.6 
These effects can be reversed by mifepristone, a progesterone 
antagonist.7 Induction of postimplantation pregnancy 
termination by the use of high dose mifepristone is related 
to placental effects of mifepristone rather than on unknown 
effects of mifepristone on the embryo, ie, preimplantation 
pregnancy termination. Low dose mifepristone has been   
shown not to affect ovulation but to alter the in vitro 
maturation of dendritic cells, which favors the immuno-
rejection of an embryo attempting to implant.8
Selective progesterone receptor 
modulators
Selective progesterone receptor modulators (SPRMs) are 
progesterone receptor ligands that exert a multitude of unique 
in vivo effects that are tissue-selective.9–12 SPRMs function 
as either agonists, antagonists, or mixed agonist/antagonists, 
depending upon the progesterone sensitive tissue affected by 
the SPRM.13,14 Ulipristal, a chemical and pharmacological 
analog of mifepristone, is a SPRM that is marketed as a 
second generation EC under the trade name, ella® (Laboratoire 
HRA Pharma, Paris, France).15–20 The pharmaco  logy, 
pharmacokinetics, efficacy, and safety of ulipristal as an EC 
have been recently reviewed.21 Classifying ulipristal as a 
contraceptive versus classifying ulipristal as a contragestive 
have been analyzed.22 “This report will use the classical 
definitions of both   abortion and contraceptive.   Abortion is 
defined as the loss of the embryo occurring either at the 
preimplantation stage or at the post-implantation stage and 
contraception is defined as the prevention of fertilization.”
ECs
ECs are employed after a single episode of either  unprotected 
intercourse or condom failure. Levonorgesterel, a first-
  generation EC, is effective as an EC if taken within 72 hours 
after intercourse and if taken in the follicular phase and prior to 
the rising levels of lutenizing hormone (LH).23,24   Mifepristone, 
but not levonorgestrel, inhibits human blastocyst attachment 
to an in vitro endometrial culture model.25 Ulipristal’s 
  effectiveness as an EC is extended up to 120 hours after 
intercourse in the follicular phase and is also effective as an 
EC if taken during rising LH levels prior to ovulation.26–29
The mechanisms of action of mifepristone and levonorg-
estrel when used for emergency contraception have been 
described.24 The mechanism of action of low dose of ulipristal 
(30 mg) as an EC has been attributed exclusively to the mecha-
nism of delaying ovulation for several days until the deposited 
sperm are no longer capable of fertilizing the ovum.27,30,31 
Because ulipristal has a long biological half-life of 32 hours, 
it is able to delay ovulation past the life span of sperm.21 
To date, there have been no reports of any immunopharma-
cologic adverse reactions attributed to the delay of ovulation 
by ulipristal. Sperm are capable of fertilizing an ovum from a 
few minutes after intercourse up to 5 days (120 hours) later by 
those sperm that were stored in the   cervical crypts. On the other 
hand, the ovum is only capable of being fertilized for 24 hours 
after ovulation.32,33 Ulipristal has a placebo effect when both 
unprotected intercourse and the administration of ulipristal 
occur more than 24 hours after ovulation. However, there is a 
unique circumstance and time period in which ulipristal would 
have a direct abortifacient effect rather than a contraceptive 
effect. When unprotected intercourse occurs within the fertility 
window (ie, less than 120 hours (5 days) before ovulation or 
not more than 24 hours after ovulation) and ulipristal is taken 
after fertilization, then ulipristal would have an abortifacient 
effect. An abortifacient effect of ulipristal can occur when 
ulipristal is taken post-fertilization but prior to implantation, 
when the progesterone levels are relatively low. The following 
analysis proposes that ulipristal unleashes an immunological 
attack on the implanting embryo.
Multiple mechanisms of action  
of ulipristal
Ulipristal binds to selective progesterone receptors in the 
uterus and corpus luteum, resulting in three abortifacient 
mechanisms: (1) failure of the decidua to develop and become 
receptive to implantation of the blastocyst, (2) failure of 
secretions of uterine glands in the decidua to maintain an 
implanted embryo, and (3) the return of spontaneous uterine 
contractions.34–36 There is potentially a fourth mechanism 
involving the immunological rejection of the blastocyst’s 
trophoblast cells in a host-versus-graft rejection mechanism 
during the embryo’s attempt to implant into the decidua. This 
fourth mechanism, proposed in this paper, involves the mIIS 
during the first 5–10 days after fertilization.37
Immunosuppression of the innate 
immune system in pregnancy
For a pregnancy to be successful, one of the many vital 
actions of progesterone is its ability to induce selective 
immune tolerance of the mIIS toward the paternal allogeneic 
embryo, beginning with fertilization and extending through 
implantation.38–44 During implantation, this induced tolerance 
of the mIIS is unique in that the mIIS is still able to provide 
a defense against the bacteria that invade the decidua.45,46 
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granulosa cells are of maternal origin, the mIIS is not 
triggered by the foreign paternal antigens on the encapsulated 
embryo. Thus, from fertilization to the shedding of the zona 
pellucida, the developing embryo is shielded from initiating 
an immunological attack.47 Activation of the innate immune 
system would result in pregnancy loss.48 After shedding 
of the zona pellucida, implantation of the blastocyst can 
begin, and several factors are involved in the initiation of 
the selective immunotolerance of an implanting paternal 
semi-allogeneic graft.49–51 For example, human leukocyte 
antigen G plays a key role in implantation by modulating 
cytokine secretion to control trophoblastic cell invasion and to 
maintain a local immunotolerance.52–58 The decidua secretes 
glycodelin, a protein with proposed   immunomodulatory 
activity during nidation.59 To avoid rejection, the villous 
trophoblast population of cells that are exposed to maternal 
blood lacks both major histocompatibility complex class I and 
class II molecules.60 Immunnotolerance is further aided by 
progesterone’s ability to stimulate both systemic and uterine 
regulatory T cells, (CD4+CD25+ Treg cells) so that anti-
inflammatory T helper (Th)-2 cells predominate over the pro-
inflammatory Th-1 cells.61–66 Th-1 cells produce inflammatory 
cytokines associated with spontaneous abortion, while 
Th-2 cells secrete anti-inflammatory cytokines associated 
with immunotolerance.67
Early pregnancy factor (EPF), progesterone-induced 
blocking factor (PIBF), and phenotypically altered   decidua 
natural killer cells (DANK) are intimately involved in 
  allowing the mIIS to set up a selective tolerance of the 
implanting embryo.68 Since both mifepristone and   ulipristal 
alter the natural functioning of progesterone receptors 
involved in EPF, PIBF, and DANK, progesterone is   prevented 
from inducing the necessary selective tolerance state of the 
mIIS cells in the decidua, the uterine stoma, and the corpus 
luteum. This allows mIIS cells to reject the implanting or 
newly implanted embryo.
ePF
Within microseconds after fertilization, the ion channels 
in the zygote’s cell membrane open resulting in a perma-
nent negative charge that sweeps across the surface of the 
zygote’s cell membrane preventing additional sperm from 
gaining access to the interior of the fertilized ovum. Then, 
within minutes after fertilization, the zygote secretes an 
enzyme that changes the zona pellucida from a sol to a gel, 
which forms an additional barrier that sperm are not able 
to penetrate and protects the embryo from both physical 
damage and cellular immunological attack as the embryo 
begins its 5–7 day journey through the fallopian tube into 
the interior of the uterus. Within hours after fertilization, the 
developing embryo begins secretion of ovum factor, which 
stimulates progesterone-primed maternal ovaries to secrete 
EPF. EPF has immunomodulatory properties, and it is an 
extra cellular form of protein chaperonin 10.69–71 EPF is the 
first of three mechanisms that suppresses the mIIS to prevent 
  immunological rejection of the embryonic trophoblast cells. 
The invading trophoblast cells of the blastocyst constitute a 
semi-allograft that would be rejected without the suppression 
of the mIIS by progesterone. Developing trophoblasts of the 
embryo take over from the ovaries and maintain the secretion 
of EPF. EPF binds to a specific lymphocyte population that 
releases soluble suppressor factors.39 Figure 1 depicts the 
proposed mechanism by which EPF suppresses the mIIS.
A variety of cellular and signaling mechanisms use 
nuclear factor (NF)-κβ to generate pro-inflammatory cytok-
ines, inflammatory mediators, and cytotoxic cells as agents 
to protect humans from infections, tumors, and carcino-
gens.72,73 NF-κβ is a ubiquitous transcription factor. Since 
NF-κB functions as the master switch in immune system’s 
  protective mechanisms, NF-κβ may operate in the rejection 
of   semi-allogenic cells.50,74,75 Thus EPF could achieve immu-
nosupression of uterine immune cells by activating I-κβ, the 
naturally occurring inhibitor of NF-κβ.76
PIBF
In pregnant mice, due to endocrine stimulation by pro-
gesterone, spleenic lymphocytes synthesize and secrete 
Zygote/
Embryo
***
Ovum
factor Ovaries Spleenic
leukocytes
Progesterone Progesterone Progesterone
pNKC
uNKC EPF PIBF
Inhibition of the
maternal innate
immune system
Figure 1 Immunosuppression of the innate immune system in pregnancy. normal 
suppression of the maternal innate immune system begins with fertilization and is a 
result of ePF and progesterone-dependent secretion of T helper-2 cytokines, the 
inhibitor of nuclear factor kappa beta, interleukin-10, and tumor growth factor beta.
Note: *When blocked or modulated by ulipristal, the maternal immune innate 
system is free to immunologically attack the trophoblast cells of the implanting 
embryo in a host-versus-graft reaction.
Abbreviations: ePF, early pregnancy factor; PIBF, progesterone-induced blocking 
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a factor that immunosuppresses the maternal immune 
system.77,78 This factor, PIBF, inhibits natural killer cell 
(NKC) cytotoxicity, stimulates production of asymmetrical 
antibodies, and increases interleukin (IL)-4 production.79,80 
The net result of PIBF is to inhibit Th-1 cytokine responses 
and increase Th-2 responses.81–85 PIBF has been shown to 
have an anti-abortive effect in mice. NKC activity has been 
shown to be significantly lower in pregnant women when 
compared with nonpregnant women. Spontaneous abor-
tions in women have been associated with increased NKC 
activity, and NKCs are recruited into the decidua during 
early pregnancy in both mice and humans. Spleenic cells 
from mice on day 8.5 of pregnancy treated with anti-PIBF 
immunoglobulin G had a fourfold increase in natural killer 
activity when sacrificed on day 10.5. Mice injected with 
mifepristone on day 8.5 of pregnancy and sacrificed on 
day 10.5 had an increased abortion rate and a decrease in 
PIBF-producing cells in the spleen.86,87 Early termination 
of pregnancy induced with mifepristone is associated with 
a disturbance of progesterone-mediated immunosuppres-
sion.88 It is reasonable to assume that ulipristal, a derivative 
of mifepristone, would exert the same effect as mifepristone 
on lymphocytes that synthesize and secrete PIBF during 
pregnancy.
Phenotypic conversion of peripheral 
nKCs (pnKCs) to uterine nKCs 
(unKCs)
NKCs provide the first line of defense of the mIIS against 
transplanted semi-allogenic cells, tumor cells, and cells 
infected with bacteria or viruses.89–95 Cytotoxic materials are 
delivered from NKCs to adverse target cells via a cellular 
structure known as an immune synapse that is composed 
of microscopic nanotubes.96–98 Chemokines and cytokines 
are secreted by the implanting embryo, resulting in the 
recruitment of maternal pNKCs (CD56dimCD16+).99 These 
pNKCs under the direct influence of progesterone undergo 
a phenotypical conversion to uNKCs (CD56brightCD16−) and 
regulate embryo development.100–102 This conversion appears 
to be controlled by the trophoblast secretion of tumor growth   
factor-beta into the local environment of the decidua.94,103 
Furthermore, chorionic gonadotrophin (hCG), secreted by 
the preimplantation developing embryo within the fallopian 
tube, contributes to maternal immunotolerance by regulating 
the Fas-Fas ligand system.104 Also, hCG is a stimulator of 
uNKC proliferation.103,105 The phenotypical uNKCs are cru-
cial for the secretion of angiogenic factors, such as vascular 
endothelial growth factor for the remodeling of the vasculature 
of the spiral arteries in formation of the placenta.106–108 
Low-dose mifepristone has been shown to act as an anti-
  implantation drug by causing a dysregulation of uNKCs during 
  implantation.3 Progesterone suppression of tumor necrosis 
factor α, IL-1β, and IL-12 is prevented by mifepristone.3,109 
It is postulated that ulipristal also acts in a similar manner to 
mifepristone in causing a   dysregulation of uNKCs, resulting 
in the destruction of the embryo by NKCs.
Summary
The mechanism of action of a low-dose ulipristal (30 mg) 
as an EC has been attributed exclusively to the delaying 
of ovulation by 5 days. This particular mechanism of 
action occurs when both unprotected intercourse and the 
administration of ulipristal occur within the fertile window. 
However, a single low dose of ulipristal has a placebo effect 
when both unprotected intercourse and the administration 
of ulipristal occurs more than 24 hours after ovulation. 
Furthermore, when unprotected intercourse occurs during the 
fertile window and the administration of ulipristal occurs after 
ovulation, then ulipristal exerts an abortifacient action. It is 
proposed that the mIIS is responsible for the destruction of the 
implanting embryo via a host-versus-graft reaction involving 
ulipristal interference with EPF, PIBF, and decidual NKCs 
within the mIIS.
Datasources
MEDLINE, PubMed, and Google Scholar databases were 
searched (1980–June 2011). Key search terms were: proges-
terone, ulipristal, mifepristone, emergency contraceptives, 
early pregnancy factor, progesterone induced blocking fac-
tor, uterine natural killer cells, and pregnancy immunosup-
pression. Search of the literature was limited to the English 
language.
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